NTX-1088

NTX-1088 · Nectin Therapeutics Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NTX-1088, covering 2025-09-09 to 2025-09-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab [Phase 1]

See pricing